Loading...
SAMG is not a good buy right now. Price is sitting on/just below near-term support with bearish momentum (MACD deterioration) and no proprietary buy signals to justify an impatient entry. With the latest quarter showing sharply weaker profitability (net income and EPS down 70%+ YoY), the risk/reward does not favor buying immediately; a better setup would be confirmation of a bounce back above the pivot (15.27) or improving momentum.
Intellectia Proprietary Trading Signals
Trend / Momentum: Bearish-to-weak. MACD histogram is negative (-0.143) and expanding lower, which typically signals worsening downside momentum.
RSI (6): 23.878, which is oversold (not neutral). This can support a short-term bounce, but oversold alone is not a reliable buy trigger when MACD is still deteriorating.
Moving Averages: Converging MAs suggest indecision/transition, but not yet a confirmed uptrend.
Key Levels:
Pattern-based forward odds: Similar-pattern stats imply modest upside probabilities (next day ~+1.14%, next week ~+3.69%, next month ~+6.77%), but these are not strong enough to override the current bearish momentum + weak fundamentals.

Oversold RSI near support (14.59 area) increases the odds of a short-term technical bounce.
Revenue grew modestly in 2025/Q3 (+2.86% YoY).
Low IV rank/percentile suggests less fear priced in, which can help if any positive catalyst appears (but none is present in the news feed).
Momentum is still deteriorating (MACD negative and expanding), which often precedes further downside before a durable bottom.
Options open-interest skew is heavily put-leaning (bearish/defensive stance).
2025/Q3 profitability sharply worsened: net income -72.56% YoY and EPS -70.83% YoY, which can weigh on investor confidence and valuation.
No recent news catalysts to reset narrative or re-rate the stock.
Latest reported quarter: 2025/Q3.
No analyst rating/price target trend data was provided, so Wall Street consensus changes cannot be confirmed. Based strictly on the provided data, the 'pros' case would lean on a potential oversold bounce and modest revenue growth, while the 'cons' case is dominated by sharply weaker earnings and bearish momentum/put-heavy positioning.
